ClinicalTrials.gg
Active, not recruitingNCT05429463neoSCORE ⅡUpdated Nov 4, 2026

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ)

A Phase 3 interventional study of Sintilimab and Carboplatin in Squamous Cell Non-small Cell Lung Cancer, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Now Active, not recruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung — 17 open to participants now, 22 under way, 4 of them phase 3. sintilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
6th of 46
250 · median 60
Started
2022
with 7 others
Phase 3
8 of 46
2 open now
Primary completion
2026-11
later than 14 of 21 live
Registered
29th of 46
by date

Among the 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by planned enrollment, is one of 8 that started in 2022, is one of 8 in phase 3, reaches primary completion later than 14 of the 21 other live ones, and was the 29th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

17 of the 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

Read the detailed description

This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell NSCLC. In this trial, eligible subjects will be randomly assigned to arm A and arm B (1:1). Subjects in arm A will receive 3 cycles of neoadjuvant sintilimab with chemotherapy and arm B will receive 4 cycles of neoadjuvant sintilimab with chemotherapy, followed by surgery within the 3-5th week after the last dose of sintilimab. After operation, both subjects in arm A and B can receive the treatment of sintilimab for up to 1 year according to the requirements of patients. The primary purpose is MPR rate of Resectable Squamous Cell NSCLC with different cycles of sintilimab combined with chemotherapy, which is defined as the percentage of participants having ≤10% viable tumor cells in the pathological examination of resected specimens.

03

Conditions studied

  • Squamous Cell Non-small Cell Lung Cancer

Keywords

  • Sintilimab
  • Squamous Cell NSCLC
  • Neoadjuvant immunochemotherapy
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form before starting any trial related procedure.Be willingness and able to undergo planned visits, protocol therapy, laboratory tests and other testing procedures.
  2. 18-75 years old, male or female.
  3. Squamous Cell Non-small cell lung cancer confirmed by cytology or histology.
  4. There must be at least one evaluable focus judged according to recist1.1 standard.
  5. Evaluation by the researchers and classified by the 8th version of AJCC TNM staging to confirm resectable stage cⅡA-ⅢB squamous NSCLC patients without any treatment before.
  6. PS 0-1.
  7. > 6 months.
  8. Adequate organ function and it should meet the following criteria:

    Absolute value of neutrophils (ANC) ≥1.5×109/L in the absence of granulocyte colony stimulating factor for the past 14 days; ≥100×109/L in the last 14 days without blood transfusion; >9g/dL in the absence of blood transfusion or erythropoietin in the last 14 days ;

    Total (TBIL)≤1.5ULN, 、AST≤ 2.5 , serum creatinine(sCr)≤1.5ULN;

    Good blood coagulation: ≤1.5 or PT≤1.5 ULN;

    Normal thyroid function: TSH within normal institutional limits. If TSH levels are abnormal but triiodothyronine (T3) and thyroxine (T4) levels are within the normal range, and the patient is deemed eligible for the study treatment following evaluation by an endocrinologist, the patient can still be enrolled;

  9. For women of reproductive age, a urine or serum pregnancy test with negative results should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1). If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. Women of nonreproductive age were defined as at least 1 year after menopause or having undergone surgical sterilization or hysterectomy. If there is a risk of conception, all subjects (both men and women) will use a medically approved highly effective (e.g., an intrauterine device, birth control pill, or condom) for the entire treatment period up to 120 days after the last study drug (or 180 days after the last chemotherapy drug).

Exclusion criteria

Exclusion Criteria:

  1. within 5 years prior to the first dose(excluding radical skin basal cell carcinoma, skin squamous cell carcinoma and / or radical resection of carcinoma in situ).
  2. Currently participating in the intervention clinical treatment, or receiving other drugs or research instruments within 4 weeks before the first dose.
  3. Patients who have had prior treatment with an , anti-PD-L1, anti-PD-L2, or drugs for another stimulation or synergistic inhibition of T cell receptor (e.g. CTLA-4, OX-40, CD137).
  4. Active diseases requiring systemic treatment (e.g. using disease improving drugs, or ) occurred within 2 years before the first dose. Alternative therapies (e.g. thyroxine, insulin or corticosteroids in physiological doses for adrenal or pituitary insufficiency) are not considered systemic treatment.
  5. Systemic glucocorticoid therapy (excluding local glucocorticoids by nasal spray, inhalation or other routes) or any other form of immunosuppressive therapy is in progress within 7 days before the first dose.

    Note: it is allowed to use physiological dose of glucocorticoid (Prednisone≤10 mg/d or equivalent drug).

  6. Received allogeneic organ transplantation (except corneal transplantation) or hematopoietic stem cell transplantation.
  7. Allergic to study drug(sintilimab, carboplatin, albumin-bound paclitaxel) components .
  8. Not fully recovered from toxicity and/ or complications caused by any intervention before treatment (≤level 1 or reach baseline, excluding fatigue or hair loss).
  9. Has a known history of (HIV) infection (HIV 1/2 antibody positive).
  10. Untreated active (defined as HBsAg positive and HBV-DNA copies>).
  11. Active (HCV antibody positive and HCV-RNA level higher than the detection limit).
  12. Inoculate the within 30 days before the first dose (cycle 1 day 1).

    Note: it is allowed to receive the injection inactivated virus vaccine for seasonal influenza within 30 days before the first dose; however, it is not allowed to accept the live attenuated influenza vaccine for intranasal medication.

  13. Pregnant or lactating women.
  14. There are any serious or uncontrollable systemic diseases, such as:

    Resting has significant abnormalities in rhythm, conduction or morphology, and the symptoms are serious and difficult to control,such as complete left bundle branch block, heart block above degree Ⅱ, ventricular arrhythmia or atrial fibrillation;

    Unstable angina, congestive heart failure, chronic heart failure with grade ≥ 2;

    Within 6 months before inclusion, there were any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, etc;

    History of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose,or having currently clinical active interstitial lung diseases;

    Active pulmonary tuberculosis;

    Active or uncontrolled infections requiring systemic treatment;

    Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;

    Poorly controlled diabetes (Fasting blood glucose (FBG)>10mmol/L);

    Urine routine test indicates that urine protein≥++, and confirmed that 24 hours proteinuria>1.0 g;

    Patients with mental disorders who are unable to cooperate with the treatment;

  15. There are medical history, disease, treatment or laboratory abnormal results that may interfere with the test results, prevent the subjects from participating in the whole process of the study, or the researchers think that participating in the study is not in the best interests of the subjects or there are other potential risks that the subjects are not suitable for the study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Arm A(3 cycles of neoadjuvant therapy)

    Neoadjuvant: Prior to surgery, participants receive up to 3 cycles (cycle length: 3 weeks) of sintilimab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel \[260 mg/m\^2, IV; given on cycle day 1\] and carboplatin \[AUC 5- 6mg/mL/min, IV; given on cycle day 1 \] . Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab \[200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks\] may be selected upon subject request for up to 1 year.

    Biological: Sintilimab · Drug: Carboplatin · Drug: Albumin-Bound Paclitaxel

  • Experimental
    Arm B(4 cycles of neoadjuvant therapy)

    Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of sintilimab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel \[260 mg/m\^2, IV; given on cycle day 1\] and carboplatin \[AUC 5- 6mg/mL/min, IV; given on cycle day 1 \] . Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab \[200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks\] may be selected upon subject request for up to 1 year.

    Biological: Sintilimab · Drug: Carboplatin · Drug: Albumin-Bound Paclitaxel

Interventions

  • BiologicalSintilimab

    200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

    Also known as: IBI308, PD-1 antibody

  • AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.

  • 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

06

What researchers measure

Primary outcomes

  1. Major pathological response rate (MPR)

    MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the pathological examination of resected specimens.

    Time frame: At time of surgery

Secondary outcomes

  1. Pathology complete response rate(pCR)

    pCR rate is defined as the percentage of participants lacking of evidence of viable tumor cells in the pathological examination of resected specimens.

    Time frame: At time of surgery

  2. Objective response rate (ORR)

    ORR is defined as the percentage of participants having a complete response or a partial response, measured by RECIST 1.1.

    Time frame: prior to surgery

  3. 2 years disease-free survival rate (DFS)

    2 years DFS rate is defined as the percentage of participants having no recurrence, distant metastasis or death within 2 years after operation.

    Time frame: 2 years postoperatively

  4. 2 years overall survival rate (OS)

    2 years OS rate is defined as the percentage of participants having no death of any cause within 2 years after operation.The Kaplan-Meier estimator will be used to estimate median OS and its 95%CI and the survival curve.

    Time frame: 2 years postoperatively

  5. 2 years event free survival (EFS)

    2 years EFS rate is defined as the percentage of participants having no radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause within 2 years after randomization.

    Time frame: 2 years after randomization

07

Study locations

1 site
08

References and documents

Publications

  • Zhang X, Shao M, Yao J, Zhao L, Li L, Chen M, Zhang Y, Liu H, Chen Z, Li B, Wu Z, Fan J, Qiu F. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer. Future Oncol. 2024 Jan;20(3):121-129. doi: 10.2217/fon-2024-0026. Epub 2024 Feb 14. PubMed 38353107 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's planned 47 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Nov 2022 → Dec 2022, primary completion Nov 2025 → Nov 2026 and completion Nov 2029 → Aug 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2022
First posted
Jun 23, 2022
StartActual
Dec 8, 2022was Nov 2022
Primary completionEst.
Nov 30, 2026was Nov 2025
CompletionEst.
Aug 1, 2030was Nov 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Start date
Nov 11, 2022→Dec 8, 2022
Nov 4, 2026
Primary completion
Nov 11, 2025→Nov 30, 2026
Nov 4, 2026
Study completion
Nov 11, 2029→Aug 1, 2030
Nov 4, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Normal thyroid function: TSH within normal institutional limits;Now Normal thyroid function: TSH within normal institutional limits. If TSH levels are abnormal but triiodothyronine (T3) and thyroxine (T4) levels are within the normal range, and the patient is deemed eligible for the study treatment following evaluation by an endocrinologist, the patient can still be enrolled;
Nov 4, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38353107 ↗
Nov 4, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38353107 ↗
    Start date Nov 11, 2022→Dec 8, 2022
    Primary completion Nov 11, 2025→Nov 30, 2026
    Study completion Nov 11, 2029→Aug 1, 2030
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Normal thyroid function: TSH within normal institutional limits;Now Normal thyroid function: TSH within normal institutional limits. If TSH levels are abnormal but triiodothyronine (T3) and thyroxine (T4) levels are within the normal range, and the patient is deemed eligible for the study treatment following evaluation by an endocrinologist, the patient can still be enrolled;
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 5 other changes: identifiers, verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05429463
Collaborators
Lanzhou University Second Hospital, Zhejiang Rongjun Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The First Affiliated Hospital of Bengbu Medical University, Ningbo No.2 Hospital, Guangdong Provincial People's Hospital, Shanghai Chest Hospital, Liaoning Cancer Hospital & Institute, Shanghai Zhongshan Hospital, Ruijin Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Affiliated Zhongshan Hospital of Dalian University, Zhejiang Cancer Hospital, Jiangxi Provincial People's Hopital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Lishui University, Changxing County Traditional Chinese Medicine Hospital, Affiliated Hospital of Jiaxing University
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Dec 8, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion